After uproar, man with breast cancer gets coverage

Tuesday, August 23rd, 2011

Raymond Johnson was due for some good news. Earlier this month, he was denied Medicaid coverage after being diagnosed with breast cancer.  But he just got the call he was waiting for: South Carolina’s Department of Health and Human Services is granting him coverage, after all. Find more info about After ...

After uproar, man with breast cancer OK’d for coverage

Monday, August 22nd, 2011

Raymond Johnson was due for some good news. Earlier this month, he was denied Medicaid coverage after being diagnosed with breast cancer.  But he just got the call he was waiting for: South Carolina’s Department of Health and Human Services is granting him coverage, after all. Find more info about After ...

Better Protection Of Human Subjects Involved In Research Proposed By HHS, USA

Saturday, July 23rd, 2011

The US Department of Health and Human Services (HHS) is proposing some new regulations aimed at improving the safety for human subjects in scientific experiments. The current regulations, known as The Common Rule have not been changed since 1991. The HHS says it is seeking feedback from the public ...

Affordable Insurance Exchanges – Providing Same Health Insurance Choices As Members Of Congress Have

Wednesday, July 13th, 2011

The HHS (US Department of Health and Human Services) has introduced its proposal - Affordable Insurance Exchanges - the aim being to have state-based competitive marketplaces where people and smaller businesses can buy private health insurance at reasonable prices. The HHS claims individuals would then have the same health insurances ...

Intercell Starts Trial In Pandemic Influenza With Its Vaccine Enhancement Patch And Provides Update To The Strategic Collaboration With GSK On Patches

Wednesday, May 4th, 2011

Today Intercell AG (VSE: ICLL) announced the start of a further trial in the field of pandemic Influenza, investigating Intercell's adjuvant patch (Vaccine Enhancement Patch - VEP) containing LT (a heat-labile toxin from E. coli) in combination with GSK's H5N1 pandemic antigen. This trial follows prior work with a non-GSK ...